Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug
-
- Ronan Desmond
- Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;
-
- Danielle M. Townsley
- Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;
-
- Bogdan Dumitriu
- Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;
-
- Matthew J. Olnes
- Hematology Department, Alaska Native Tribal Health Consortium, Anchorage, AK;
-
- Phillip Scheinberg
- Hospital Sao Jose – Hospital Beneficencia Portuguesa de Sao Paulo, Sao Paulo, Brazil;
-
- Margaret Bevans
- Nursing Research and Translational Science, National Institutes of Health, Bethesda, MD;
-
- Ankur R. Parikh
- Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;
-
- Kinneret Broder
- Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;
-
- Katherine R. Calvo
- Laboratory Medicine, National Institutes of Health, Bethesda, MD; and
-
- Colin O. Wu
- Office of Biostatistics Research, National Heart, Lung, and Blood Institute, Bethesda, MD
-
- Neal S. Young
- Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;
-
- Cynthia E. Dunbar
- Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;
抄録
<jats:title>Key Points</jats:title> <jats:p>Eltrombopag promotes hematopoiesis in patients with severe aplastic anemia by stimulating stem and progenitor cells. Eltrombopag can be discontinued safely in robust responders with maintenance of hematopoiesis.</jats:p>
収録刊行物
-
- Blood
-
Blood 123 (12), 1818-1825, 2014-03-20
American Society of Hematology